Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1972 1
1973 2
1974 1
1975 3
1979 4
1980 1
1983 2
1984 4
1985 2
1986 1
1987 5
1988 2
1989 6
1990 10
1991 4
1992 7
1993 3
1994 3
1995 4
1996 7
1997 9
1998 1
1999 11
2000 8
2001 17
2002 7
2003 8
2004 12
2005 14
2006 34
2007 28
2008 37
2009 37
2010 29
2011 30
2012 29
2013 24
2014 38
2015 39
2016 33
2017 45
2018 33
2019 28
2020 34
2021 37
2022 23
2023 22
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

684 results

Results by year

Filters applied: . Clear all
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic essential thrombocythemia (ET) in its presentation. Approximately 15% of patients with ET or polycythemia vera (PV) might p …
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former mi …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively characterized by clonal erythrocytosis and thrombocytosis; other disease features include leukocytosis, splenomegaly, thrombosis, bleeding …
DISEASE OVERVIEW: Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms (MPN) respectively chara …
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26. Am J Hematol. 2023. PMID: 37357958 Review.
DISEASE OVERVIEW: Polycythemia vera (PV) is a JAK2-mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other features include leukocytosis, thrombocytosis, splenomegaly, pruritus, constitutional symptoms, microcirculatory disturbances, and increased …
DISEASE OVERVIEW: Polycythemia vera (PV) is a JAK2-mutated myeloproliferative neoplasm characterized by clonal erythrocytosis; other feature …
Essential thrombocythemia: challenges in clinical practice and future prospects.
Godfrey AL, Green AC, Harrison CN. Godfrey AL, et al. Blood. 2023 Apr 20;141(16):1943-1953. doi: 10.1182/blood.2022017625. Blood. 2023. PMID: 36379024 Free article. Review.
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the molecular pathogenesis and which patients may have greatest risk of progression or vascular events. ...
Essential thrombocythemia (ET) was first described in 1934, and subsequently, progress has been made in better understanding the mole …
Genetic basis and molecular profiling in myeloproliferative neoplasms.
Luque Paz D, Kralovics R, Skoda RC. Luque Paz D, et al. Blood. 2023 Apr 20;141(16):1909-1921. doi: 10.1182/blood.2022017578. Blood. 2023. PMID: 36347013 Free PMC article. Review.
The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed according to the World Health Organization (WHO) and international consensus classification (ICC) criteria. ...
The 3 subtypes, that is, polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF), are diagnosed accor …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by clonal thrombocytosis; clinical course is often indolent but might be interrupted by thrombotic or hemorrhagic complications, microc …
OVERVIEW: Essential thrombocythemia is a Janus kinase 2 (JAK2) mutation-prevalent myeloproliferative neoplasm characterized by …
[Myelofibrosis: A review].
Genthon A, Killian M, Mertz P, Cathebras P, Gimenez De Mestral S, Guyotat D, Chalayer E. Genthon A, et al. Rev Med Interne. 2021 Feb;42(2):101-109. doi: 10.1016/j.revmed.2020.08.018. Epub 2020 Nov 23. Rev Med Interne. 2021. PMID: 33243417 Review. French.
Myelofibrosis is a BCR-ABL1-negative chronic myeloproliferative neoplasm that includes primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. It is characterized by stem cell-derived clonal proliferation that is often …
Myelofibrosis is a BCR-ABL1-negative chronic myeloproliferative neoplasm that includes primary myelofibrosis, post-polycythemia vera myelofi …
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W, Kulozik AE; THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Stockklausner C, et al. Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12. Ann Hematol. 2021. PMID: 33712866 Free PMC article. Review.
Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. ...Here we summarize literature on classification, diagnostics, and clinical management of childhood thrombocytosis....
Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation. ...Here we summarize literature on …
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms.
Vainchenker W, Kralovics R. Vainchenker W, et al. Blood. 2017 Feb 9;129(6):667-679. doi: 10.1182/blood-2016-10-695940. Epub 2016 Dec 27. Blood. 2017. PMID: 28028029 Free article. Review.
This explains why JAK2V617F is associated with polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whereas CALR and MPL mutants are found in ET and PMF. ...
This explains why JAK2V617F is associated with polycythemia vera, essential thrombocythemia (ET), and primary myelofibrosis (PMF) whe …
Momelotinib: First Approval.
Keam SJ. Keam SJ. Drugs. 2023 Dec;83(18):1709-1715. doi: 10.1007/s40265-023-01964-8. Drugs. 2023. PMID: 37989928 Review.
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been developed for the treatment of myelofibrosis (MF). In September 2023, momelotinib was approved in the USA for the treatment of intermediate or h …
Momelotinib (OJJAARA) is an oral Janus kinase 1 and 2 (JAK1/JAK2) and activin A receptor, type I (ACVR1) inhibitor that has been deve …
684 results